+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic value of class III b-tubulin (TUBB3) in operable non-small cell lung cancer (NSCLC) and predictive value for adjuvant cisplatin-based chemotherapy (CT): A validation study on three randomized trials



Prognostic value of class III b-tubulin (TUBB3) in operable non-small cell lung cancer (NSCLC) and predictive value for adjuvant cisplatin-based chemotherapy (CT): A validation study on three randomized trials



Journal of Clinical Oncology 26(15_suppl): 7506-7506



NlmCategory="UNASSIGNED">7506 Background: The IALT and JBR.10 randomized trials both demonstrated the survival advantage of adjuvant platinum-based CT for patients with resected NSCLC. We previously showed by immunohistochemistry (IHC) that high TUBB3 expression might correlate with greater benefit from adjuvant vinorelbine/cisplatin CT in an analysis of tumor tissues from 265 patients in the JBR.10 trial. Here, we sought to verify the previous suggestions in the IALT trial. Since some CT regimens in the IALT trial did not include an anti-tubulin agent, we also tested the hypothesis that the value of TUBB3 expression in predicting benefit from CT was specific to anti-tubulin containing regimens. Tissue microarrays representing 737 patients on the IALT trial were stained for TUBB3. A score was generated based on the intensity and the proportion of positive-staining tumor cells in each case. Patients were classified as having high or low TUBB3 expression based on the median score. Correlations were assessed between TUBB3 and known prognostic factors, disease-free survival (DFS), overall survival (OS) and CT effect through stratified logistic and Cox models. High TUBB3 expression significantly correlated with adenocarcinoma histology (p=0.0001), lymphatic (p=0.03) and vascular invasion (p=0.01), and DFS (HR 1.26, 95% CI 1.01-1.58, p = 0.04), with a similar trend in OS (p=0.12). There was no significant interaction seen between TUBB3 status and treatment assignment in predicting DFS (HR for CT effect in high versus low TUBB3 groups =0.92, p=0.71) or OS (HR=1.01, p=0.98), nor when the analysis was restricted to anti-tubulin containing regimens (DFS: HR=0.90, p=0.71; OS: HR=0.93, p=0.82). High TUBB3 expression is an adverse prognostic factor in IALT, in concordance with prior observations in JBR.10. However, unlike what was suggested in JBR.10, in IALT TUBB3 expression did not correlate with benefit from adjuvant chemotherapy. More insight into the role of TUBB3 will be given at the time of the meeting when the results of IALT together with ANITA and CALGB 9633 trials will be available. No significant financial relationships to disclose.

(PDF emailed within 1 workday: $29.90)

Accession: 058637683

Download citation: RISBibTeXText

PMID: 27947282


Related references

Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Annals of Oncology 23(1): 86-93, 2012

Class III beta tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: Analysis of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study JBR.10. Journal of Clinical Oncology 24(18_suppl): 7051-7051, 2016

Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clinical Cancer Research 13(3): 994-999, 2007

Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis. Journal of Thoracic Oncology 11(6): 850-861, 2017

Non-cancer-related mortality after cisplatin-based adjuvant chemotherapy for non-small cell lung cancer: a study-level meta-analysis of 16 randomized trials. Medical Oncology 30(3): 641, 2014

Analysis of ERCC1, BRCA1, RRM1 and TUBB3 as predictors of prognosis in patients with non-small cell lung cancer who received cisplatin-based adjuvant chemotherapy: A prospective study. Oncology Letters 11(1): 299-305, 2016

The prognostic role of the class III β-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane/vinorebine-based chemotherapy: a meta-analysis. Plos One 9(4): E93997, 2014

A randomized phase III trial of adjuvant chemotherapy with cisplatin and vindesine followed by UFT for completely resected pathologic (p-) stage IIIA-N2 non-small cell lung cancer (NSCLC): West Japan Study Group for Lung Cancer Surgery (WJSG) - the 5 th Study. Journal of Clinical Oncology 23(16_suppl): 7262-7262, 2016

Long-term results of the International Adjuvant Lung Cancer Trial (IALT) evaluating adjuvant cisplatin-based chemotherapy in resected non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 26(15_suppl): 7507-7507, 2016

High expression levels of class III β-tubulin in resected non-small cell lung cancer patients are predictive of improved patient survival after vinorelbine-based adjuvant chemotherapy. Oncology Letters 6(1): 220-226, 2013

Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG). European Journal of Cardio-Thoracic Surgery 15(4): 438-443, 1999

Lack of predictive value of reticulocalbin-1 and GST-Pai alterations for efficacy of postoperative adjuvant chemotherapy consisting of cisplatin plus vindesine in patients with p-stage IIIA-N2 non-small cell lung cancer (NSCLC) (JCOG9304A). Journal of Clinical Oncology 23(16_suppl): 7316-7316, 2016

Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy. Cancer ChemoTherapy and Pharmacology 74(4): 777-786, 2015

A randomized phase II feasibility study of adjuvant cisplatin/docetaxel (CisD) or cisplatin/vinorelbine (CisV) in patients (pts) resected stage IB-II non-small cell lung cancer (NSCLC): Interim analysis. Journal of Clinical Oncology 26(15_suppl): 7594-7594, 2016

Gemcitabine-based chemotherapy for non-small cell lung cancer (NSCLC)--a review of 30 randomized trials. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 29(9): 1583-1596, 2002